• helpdesk@Lucintel.com
  • |
  • +1 972 636 5056
  • |
  • Login
  • |
  • Register
  • |
...

Request the impact of COVID-19 in this market at no additional cost. Buy it today to get an advantage.

Request Now


The global pharmaceutical industry is expected to reach $1,241 billion by 2016, growing at a CAGR of 5.7%. The fragmented market has observed some changes in the competitive landscape during the last five years. The top players are expanding their footprints in the emerging markets of China, India, Brazil, Latin America, and Easte

rn Europe. They are strengthening their technological and R&D structure by targeted merger and acquisition activities to help develop and market innovative drugs.

Lucintel, a leading global management consulting and market research firm, has conducted a competitive analysis on the global drugs industry and presents its findings in “Top Five Global Pharmaceutical Companies: Performance, Strategies and Competitive Analysis.” This report briefly discusses the subject companies, their geographic footprints, financial metrics, market performance, marketing and corporate strategies, and provides SWOT analysis of each.

The report indicates that increased regulation of the pharmaceutical industry is expected to increase the industry’s cost structure and reduce revenue as getting drugs to market becomes a longer and more expensive process. Regulatory approval for the introduction of biogenerics/biosimilars, generic versions of biologic drugs, increases the threat of uncertainty to the pharmaceutical market.

Lucintel projects the major drivers of the industry. Growth in sectors such as health awareness among populations, R&D expenditures, sales of prescribed medicine and demand for generic medicines are expect to continue to provide huge demand for medicines. Various governments’ increased spending in infectious and chronic degenerative diseases as well as anti-diabetes and cardiovascular drugs have driven the growth in sales of the pharmaceutical industry.

The report gives an overview of the top five global pharmaceutical companies:
 
  • GlaxoSmithKline Plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi-Aventis
The industry witnessed increasing awareness and affordability of patients who prefer self-diagnosis and treatment at home.

Pharmaceutical companies competitive analysis report will save hundreds of hours of your own personal research time and will significantly benefit you in expanding your business opportunities in global pharmaceutical companies industry. In today’s chaotic economy, you need every advantage that you can find to keep ahead in your business

In Lucintel's newest competitive research study on the world's pharmaceutical companies, we thoroughly profile following five companies with detailed competitive assessments:
 
  • GlaxoSmithKline Plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi-Aventis

The detailed analysis of each company offers a critical view into key strategic areas, including:
 
  • Company overview          
  • Benchmarking (financial & market)
  • SWOT analysis         
  • Product positioning
  • Marketing strategy and tactics    
  • Corporate strategy
To make any investment, business or strategic decisions, you need adequate and timely information. Pharmaceutical companies competitive analysis market report fulfills this core need. This is an indispensable reference guide for industry executives who are dealing with pharmaceutical companies industry.

Some of the features of Top Five Global Pharmaceutical Companies: Performance, Strategies and Competitive Analysis market intelligence report are:
 
  • Market size estimates in terms of (US $) value by segments of the global pharmaceutical companies
  • Regional analysis: global pharmaceutical companies breakdown by key regions (e.g., North America, Europe, APAC and ROW)
  • Market trends, drivers and forecasts
  • Competitive benchmarking of each players against their financial & market strength
  • Global and regional market share estimates for the top players
  • Product line overview and positioning of top players
  • SWOT analysis of the leaders
  • Marketing strategy and tactics    
  • Corporate strategy
  • More than 128 valuable figures/charts and 42 tables are provided in this report
     
 1. Executive Summary  

 2. Market Definition and Scope  

 3. Market Opportunity  

 4. Competitive Benchmarking (Financial and Market)  

 5. Company Profile on Following Parameters  

 6. Profiles on Following Companies  
 6.1. GlaxoSmithKline Plc  
 6.2. Merck & Co Inc  
 6.3. Novartis AG  
 6.4. Pfizer Inc  
 6.5. Sanofi Aventis  

List of Figures
 
CHAPTER 3. Market Opportunity
Figure 3.1: Supply chain for pharmaceutical market
Figure 3.2: Global pharmaceutical industry annual trend 2006-2011 (US $B)
Figure 3.3: Global pharmaceutical industry regional trend 2006-2011 (US $B)
Figure 3.4: Global pharmaceutical industry regional trend 2006-2011 (%)
Figure 3.5: Global pharmaceutical industry segment trend 2006-2011 (US $B)
Figure 3.6: Global pharmaceutical industry segment trend 2006-2011 (%)
Figure 3.7: Global pharmaceutical industry opportunity by region
Figure 3.8: Global pharmaceutical industry opportunity by segment
    
CHAPTER 4.Competitive Benchmarking (Financial and Market)
Figure 4.1: Top five pharmaceutical companies – financial benchmarking
Figure 4.2: Global top five pharmaceutical companies gross profit and net profit analysis – 2011
Figure 4.3: Financial analysis – growth leadership quadrant (2011)
Figure 4.4: Market share of top players 2006
Figure 4.5: Market share of top players 2011
Figure 4.6: 2006 Market share analysis
Figure 4.7: 2011 Market share analysis
Figure 4.8: Global market share analysis 2011
Figure 4.9: Global market fragmentation 2011  
Figure 4.10: Market value North America: (US $B)
Figure 4.11: Market value Europe: (US $B)
Figure 4.12: Market value Asia Pacific: (US $B)
Figure 4.13: Market value Row: (US $B)
Figure 4.14: Regional revenue evaluation 2011(US $M)
Figure 4.15: Regional revenue evaluation 2011(%)
Figure 4.16: North American revenue trend for top players 2007-2011 (US $B)
Figure 4.17: Europe revenue trend for top players 2007-2011 (US $B)
Figure 4.18: Asia Pacific revenue trend for top players 2007-2011 (US $B)
Figure 4.19: Row revenue trend for top players 2007-2011 (US $B)
Figure 4.20: Lucintel triad - top five major players
 
CHAPTER 5. Company Profile of GlaxoSmithKline Plc
Figure 5.1: GlaxoSmithKline Plc’s revenue by business structure 2011
Figure 5.2: Lucintel Triad – GlaxoSmithKline Plc
Figure 5.3: Financial benchmarking GlaxoSmithKline Plc against top three and top five industry players’ average
Figure 5.4: Financial benchmarking of GlaxoSmithKline Plc against Top Five best
Figure 5.5: Global industry revenue trend Vs GlaxoSmithKline Plc (2007-2011) in US $B
Figure 5.6: Global market share trend for GlaxoSmithKline Plc (2007-2011) in (%)
Figure 5.7: North American industry revenue trend Vs GlaxoSmithKline Plc 2007-2011 in (US $B)
Figure 5.8: European industry revenue trend Vs GlaxoSmithKline Plc 2007-2011 in (US $B)
Figure 5.9: APAC industry revenue trend Vs GlaxoSmithKline Plc 2007-2011 in (US $B)
Figure 5.10: ROW industry revenue trend Vs GlaxoSmithKline Plc 2007-2011 in (US $B)
Figure 5.11: North American market share trend Vs GlaxoSmithKline Plc 2007-2011 in (%)
Figure 5.12: European market share trend Vs GlaxoSmithKline Plc 2007-2011 in (%)
Figure 5.13: APAC market share trend Vs GlaxoSmithKline Plc 2007-2011 in (%)
Figure 5.14: ROW market share trend Vs GlaxoSmithKline Plc 2007-2011 in (%)
Figure 5.15: GlaxoSmithKline Plc trend in R&D expenses 2007-2011 in US $M
Figure 5.16: GlaxoSmithKline Plc trend in R&D expenses percentage of total revenue
Figure 5.17: Comparison of GlaxoSmithKline Plc SE R&D expenditure Vs top three & top   five players average 2011
Figure 5.18: GlaxoSmithKline Plc productivity 2007-2011 (US $M)
Figure 5.19: GlaxoSmithKline Plc fixed asset value 2007-2011 (US $M)
Figure 5.20: Strategic execution
 
CHAPTER 6. Company Profile of Merck & Co., Inc.
Figure 6.1: Merck & Co., Inc. revenue by business structure 2011
Figure 6.2: Lucintel triad – Merck & Co., Inc.
Figure 6.3: Financial benchmarking of Merck & Co., Inc. against top three and top five industry players’ average
Figure 6.4: Financial benchmarking of Merck & Co., Inc. against Top five best
Figure 6.5: Global industry revenue trend Vs Merck & Co., Inc. (2007-2011) in (US $B)
Figure 6.6: Global market share trend for Merck & Co., Inc. (2007-2011) in (%)
Figure 6.7: North American industry revenue trend Vs Merck & Co., Inc. (2007-2011) in (US $B)
Figure 6.8: European industry revenue trend Vs Merck & Co., Inc. (2007-2011) in (US $B)
Figure 6.9: APAC industry revenue trend Vs Merck & Co., Inc. (2007-2011) in (US $B)
Figure 6.10: ROW industry revenue trend Vs Merck & Co., Inc. (2007-2011) in (US $B)
Figure 6.11: North American market share trend Vs Merck & Co., Inc. (2007-2011) in (%)
Figure 6.12: European market share trend Vs Merck & Co., Inc. (2007-2011) in (%)
Figure 6.13: APAC market share trend Vs Merck & Co., Inc.  (2007-2011) in (%)
Figure 6.14: ROW market share trend Vs Merck & Co., Inc. (2007-2011) in (%)
Figure 6.15: Merck & Co., Inc. trend in R&D expenses 2007-2011 in US $M
Figure 6.16: Merck & Co., Inc. trend in R&D expenses Percentage of total revenue
Figure 6.17: Comparison of Merck & Co., Inc. R&D expenditure vs top three & top five players average 2011
Figure 6.18: Merck & Co., Inc. productivity: 2007-2011 in (US $M)
Figure 6.19: Merck & Co., Inc. fixed asset value: 2007-2011 in (US $M)
Figure 6.20: Strategic execution
 
CHAPTER 7. Company Profile of Novartis AG
Figure 7.1: Novartis AG revenue by business structure 2011
Figure 7.2: Lucintel triad - Novartis AG
Figure 7.3: Financial benchmarking of Novartis AG against top three and top five industry players’ average
Figure 7.4: Financial benchmarking of Novartis AG against Top five best
Figure 7.5: Global industry revenue trend Vs Novartis AG (2007-2011) in (US $B)
Figure 7.6: Global market share trend for Novartis AG (2007-2011) in (%)
Figure 7.7: North American industry revenue trend Vs. Novartis AG 2007-2011 in (US $B)
Figure 7.8: European industry revenue trend Vs Novartis AG 2007-2011 in (US $B)
Figure 7.9: APAC industry revenue trend Vs Novartis AG 2007-2011 in (US $B)
Figure 7.10: ROW industry revenue trend Vs Novartis AG 2007-2011 in (US $B)
Figure 7.11: North American market share trend Vs Novartis AG 2007-2011 in (%)
Figure 7.12: European market share trend Vs Novartis AG 2007-2011 in (%)
Figure 7.13: APAC market share trend Vs DuPont 2007-2011 in (%)
Figure 7.14: ROW market share trend Vs DuPont 2007-2011 in (%)
Figure 7.15: Novartis AG trend in R&D expenses 2007-2011 in US $M
Figure 7.16: Novartis AG trend in R&D expenses Percentage of total revenue
Figure 7.17: Comparison of Novartis AG SE R&D expenditure Vs top three & top five players average 2011
Figure 7.18: Novartis AG productivity: 2007-2011 in (US $M)
Figure 7.19: Novartis AG fixed asset value: 2007-2011 in (US $M)
Figure 7.20: Strategic execution
 
CHAPTER 8. Company Profile of Pfizer, Inc.
Figure 8.1: Pfizer, Inc. revenue by business structure 2011
Figure 8.2: Lucintel triad – Pfizer, Inc.
Figure 8.3: Financial benchmarking of Pfizer, Inc. against top three and top five industry players’ average
Figure 8.4: Financial benchmarking of Pfizer, Inc. against Top five best
Figure 8.5: Global industry revenue trend Vs Pfizer, Inc. (2007-2011) in (US $B)
Figure 8.6: Global market share trend for Pfizer, Inc. (2007-2011) in (%)
Figure 8.7: North American industry revenue trend Vs Pfizer, Inc. (2007-2011) in (US $B)
Figure 8.8: European industry revenue trend Vs Pfizer, Inc. l (2007-2011) in (US $B)
Figure 8.9: APAC industry revenue trend Vs Pfizer, Inc. (2007-2011) in (US $B)
Figure 8.10: ROW industry revenue trend Vs Pfizer, Inc. (2007-2011) in (US $B)
Figure 8.11: North American market share trend Vs Pfizer, Inc. (2007-2011) in (%)
Figure 8.12: European market share trend Vs Pfizer, Inc. l (2007-2011) in (%)
Figure 8.13: APAC market share trend Vs Pfizer, Inc. (2007-2011) in (%)
Figure 8.14: ROW market share trend Vs Pfizer, Inc. (2007-2011) in (%)
Figure 8.15: Pfizer, Inc. trend in R&D expenses 2007-2011 in US $M
Figure 8.16: Pfizer, Inc. trend in R&D expenses Percentage of total revenue
Figure 8.17: Comparison of Pfizer, Inc. R&D expenditure vs top three & top five players average 2011
Figure 8.18: Pfizer, Inc. productivity: 2007-2011 in (US $M)
Figure 8.19: Pfizer, Inc. fixed asset value: 2007-2011 in (US $M)
Figure 8.20: Strategic execution
 
 
CHAPTER 9. Company Profile of Sanofi-Aventis
Figure 9.1: Sanofi-Aventis revenue by business structure 2011
Figure 9.2: Lucintel triad – Sanofi-Aventis
Figure 9.3: Financial benchmarking of Sanofi-Aventis against top three and top five industry players’ average
Figure 9.4: Financial benchmarking of Sanofi-Aventis against Top five best
Figure 9.5: Global industry revenue trend Vs Sanofi-Aventis (2007-2011) in (US $B)
Figure 9.6: Global market share trend for Sanofi-Aventis (2007-2011) in (%)
Figure 9.7: North American industry revenue trend Vs Sanofi-Aventis (2007-2011) in (US $B)
Figure 9.8: European industry revenue trend Vs Sanofi-Aventis (2007-2011) in (US $B)
Figure 9.9: APAC industry revenue trend Vs Sanofi-Aventis (2007-2011) in (US $B)
Figure 9.10: ROW industry revenue trend Vs Sanofi-Aventis (2007-2011) in (US $B)
Figure 9.11: North American market share trend Vs Sanofi-Aventis (2007-2011) in (%)
Figure 9.12: European market share trend Vs Sanofi-Aventis (2007-2011) in (%)
Figure 9.13: APAC market share trend Vs Sanofi-Aventis (2007-2011) in (%)
Figure 9.14: ROW market share trend Vs Sanofi-Aventis (2007-2011) in (%)
Figure 9.15: Sanofi-Aventis trend in R&D expenses 2007-2011 in US $M
Figure 9.16: Sanofi-Aventis trend in R&D expenses Percentage of total revenue
Figure 9.17: Comparison of Sanofi-Aventis R&D expenditure vs top three & top five players average 2011
Figure 9.18: Sanofi-Aventis productivity: 2007-2011 in (US $M)
Figure 9.19: Sanofi-Aventis fixed asset value: 2007-2011 in (US $M)
Figure 9.20: Strategic execution
 
 
 
List of Tables
 
CHAPTER 3. Market Opportunity
Table 3.1: Industry parameters of global pharmaceutical industry
Table 3.2: Regional revenue growth rate
Table 3.3: Segment revenue growth rate
 
CHAPTER 4. Competitive Benchmarking (Financial and Market)
Table 4.1: Financial benchmarking of top five global pharmaceutical companies
Table 4.2: Key financial parameters for top five pharmaceutical companies
Table 4.3: Competitors based on markets served
Table 4.4: Lucintel triad - Top five major players
 
CHAPTER 5. Company Profile of GlaxoSmithKline Plc
Table 5.1: Market served – GlaxoSmithKline Plc
Table 5.2: Lucintel triad – GlaxoSmithKline Plc
Table 5.3: Financial Benchmarking of GlaxoSmithKline Plc against best and against Top three and top five industry players’ average
Table 5.4: Strategic execution – product positioning by segment
Table 5.5: Strategic execution – perceived customer value / quality
Table 5.6: Strategic execution – promotion / communications
Table 5.7: Strategic execution – product distribution by region
 
CHAPTER 6. Company Profile of Merck & Co., Inc.
Table 6.1:  Market served: Merck & Co., Inc.
Table 6.2:  Lucintel triad – Merck & Co., Inc.
Table 6.3:  Financial Benchmarking of Merck & Co., Inc. against best and against Top three and Top five industry players’ average
Table 6.4:  Strategic execution – product positioning by segment
Table 6.5:  Strategic execution – perceived customer value / quality
Table 6.6:  Strategic execution – promotion / communications
Table 6.7:  Strategic execution – product distribution by region
 
CHAPTER 7. Company Profile of Novartis AG  
Table 7.1: Market served – Novartis AG  
Table 7.2: Lucintel triad – Novartis AG  
Table 7.3: Financial benchmarking of Novartis AG against best and against Top three and Top five industry players’ average
Table 7.4: Strategic execution – product positioning by segment
Table 7.5: Strategic execution – perceived customer value / quality
Table 7.6: Strategic execution – promotion / communications
Table 7.7: Strategic execution – product distribution by region
 
CHAPTER 8. Company Profile of Pfizer, Inc.
Table 8.1: Market served – Pfizer, Inc.
Table 8.2: Lucintel triad – Pfizer, Inc.
Table 8.3: Financial benchmarking of Pfizer, Inc. against best and against Top three and Top five industry players’ average
Table 8.4: Strategic execution – product positioning by segment
Table 8.5: Strategic execution – perceived customer value / quality
Table 8.6: Strategic execution – promotion / communications
Table 8.7: Strategic execution – product distribution by region
 
CHAPTER 9. Company Profile of Sanofi-Aventis
Table 9.1: Markets Served – Sanofi-Aventis
Table 9.2: Lucintel triad – Sanofi-Aventis
Table 9.3: Financial Benchmarking of Sanofi-Aventis against best and against Top three and top five industry players’ average
Table 9.4: Strategic execution – product positioning by segment
Table 9.5: Strategic execution – perceived customer value / quality
Table 9.6: Strategic execution – promotion / communications
Table 9.7: Strategic execution – product distribution by region
 
.

Buy full report or by chapter as follows

Price by License Type:
[-] Hide Chapter Details
[Chapter Number] [Chapter Name] [Chapter Number Of Pages] [Chapter Price]
Title/Chapter Name Pages Price
Full Report: Top Five Global Pharmaceutical Companies: Performance, Strategies and Competitive Analysis, Full Report $ 1,980
More than 128 valuable figures/charts and 42 tables are provided in this report
 
Lucintel has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets / applications and served 1,000+ clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
  • In-depth interviews of the major players in this market
  • Detailed secondary research from competitors’ financial statements and published data
  • Extensive search of published works, market and database information with industry news, company press releases, and customer intentions
  • A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted in the supply chain of this market to estimate market share, market size, trends, drivers, challenges and forecasts in the market. Below is a brief summary of primary interviews conducted by both job function and region.


Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis on it. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of the Lucintel research process.

 

Please sign in below to get report brochure - Top Five Global Pharmaceutical Companies.

At Lucintel, we respect your privacy and maintain the confidentiality of information / data provided by you
(Please enter your corporate email. * These fields are mandatory )